|
|
|
|
| LEADER |
01854nam a2200337 u 4500 |
| 001 |
EB001888674 |
| 003 |
EBX01000000000000001052035 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200106 r ||| eng |
| 245 |
0 |
0 |
|a CADTH Canadian Drug Expert Committee recommendation: Fluticasone Propionate (Aermony respiclick -- Teva Canada Innovation)
|h Elektronische Ressource
|b indication : maintenance treatment of asthma in patients 12 years of age and older
|
| 246 |
3 |
1 |
|a Fluticasone Propionate (Aermony respiclick -- Teva Canada Innovation)
|
| 246 |
3 |
1 |
|a Drug reimbursement recommendation Fluticasone Propionate (Aermony RespiClick)
|
| 250 |
|
|
|a Final
|
| 260 |
|
|
|a Ottawa (ON)
|b CADTH
|c 2018, December 21, 2018
|
| 300 |
|
|
|a 1 PDF file (8 pages)
|
| 653 |
|
|
|a Insurance, Health, Reimbursement
|
| 653 |
|
|
|a Fluticasone / economics
|
| 653 |
|
|
|a Child
|
| 653 |
|
|
|a Canada
|
| 653 |
|
|
|a Asthma / drug therapy
|
| 653 |
|
|
|a Fluticasone / therapeutic use
|
| 653 |
|
|
|a Cost-Benefit Analysis
|
| 710 |
2 |
|
|a CADTH Canadian Drug Expert Committee
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH common drug review
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK541457
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
|
|a 330
|
| 520 |
|
|
|a The CADTH Canadian Drug Expert Committee recommends that fluticasone propionate multi-dose dry powder inhaler be reimbursed for the maintenance treatment of steroid-responsive bronchial asthma as a prophylactic therapy in patients 12 years of age and older, if the following condition is met: Fluticasone propionate multi-dose dry powder inhaler should provide cost savings for drug plans relative to the lowest priced alternative inhaled corticosteroid reimbursed for the treatment of asthma
|